Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI) is at the forefront of using data and artificial intelligence (AI) to create personalized cancer treatments, aiming for more effective therapies and better patient outcomes. The company's mission revolves around precision medicine in cancer diagnosis, leveraging several key resources:
- Database: A comprehensive database of clinically validated historical and outcome data from patient tumors.
- CLIA-Certified Lab: An in-house Clinical Laboratory Improvement Amendments (CLIA) certified lab.
- Smart Tumor Profiling: A patient-derived tumor profiling platform that offers intelligent insights.
- Bioinformatics AI Platform: An advanced AI platform for in-house bioinformatics.
- Innovative Tumor Growth: Techniques for growing tumors in the lab to rapidly develop patient-specific treatment options.
- FDA-Approved System: The FDA-approved STREAMWAY System for automated medical fluid waste management.
Predictive Oncology's business is structured across three main segments:
- Pittsburgh Segment: Focuses on AI applications using a proprietary biobank with over 150,000 tumor samples and creates 3D culture models for drug development.
- Birmingham Segment: Provides contract research services targeting solubility improvements, stability studies, and protein production.
- Eagan Segment: Produces the FDA-cleared STREAMWAY System for medical fluid disposal, driving the majority of the company's revenue.
Recent achievements highlight the company's collaborative efforts with pharmaceutical, diagnostic, and biotech industries:
- Hosted an investor call and webcast on November 14th, providing insights into future strategies and financial performance.
- Presented a study in collaboration with UPMC Magee-Womens Hospital, utilizing AI to predict ovarian cancer survival outcomes better than clinical data alone.
- Announced a partnership with FluGen to develop a stable intranasal flu vaccine, leveraging Predictive Oncology鈥檚 biologics capabilities.
- Unveiled a proprietary 3D cell culture model to enhance cancer drug discovery.
- Introduced a new platform for functional and stable G-Protein Coupled Receptors (GPCRs), targeting advancements in cancer therapeutics.
Predictive Oncology's AI platform, PEDAL, has been validated to predict tumor sample responses to drug compounds with 92% accuracy. This platform, combined with the company's biobank of over 150,000 tumor samples and CLIA lab facilities, positions Predictive Oncology as a leader in AI-driven drug discovery and development.
Predictive Oncology (NASDAQ: POAI) has developed a novel stem cell expression system for producing functional G-Protein Coupled Receptors (GPCRs), important for cancer research.
GPCRs play a significant role in cancer tumorigenesis and represent over 30% of the therapeutic drug market, valued at nearly $3.5 billion in 2022, with an annual growth rate of 5% through 2030.
The company has filed intellectual property protection for its proprietary GPCR expression platform, which is expected to create significant partnering opportunities in drug discovery and development.
This platform will be combined with their High-Throughput Self-Interaction Chromatography (HSC鈩�) technology to enhance the solubility and stability of GPCRs, addressing existing challenges in the field.
The new technology is anticipated to launch later this year or early 2025, opening up a multi-billion-dollar market opportunity.
Predictive Oncology (NASDAQ: POAI) has launched a unique 3D cell culture model to enhance cancer drug discovery and future drug development. These organ-specific in vitro models better mimic human tissue compared to traditional 2D assays, allowing for more accurate clinical outcome predictions and optimized candidate selection for clinical trials.
The global 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, driven by applications in pharmaceuticals, regenerative medicine, cancer research, and toxicology. The technology aims to reduce time-to-market and costs, decrease animal testing, and improve clinical trial efficiency.
The company's efforts in developing 3D organoids and spheroids, enhanced by AI and machine learning, have shown promising results, with recent presentations at the Society for Laboratory Automation and Screening (SLAS) in Boston.
Predictive Oncology (NASDAQ: POAI) announced that CEO Raymond Vennare will present at the BIO International Convention 2024 in San Diego from June 3-6. Vennare will discuss the company's AI-driven drug discovery capabilities, which leverage a proprietary biobank of over 150,000 tumor samples. The firm's assets include advanced AI, a CLIA-certified wet lab, and pathology slides, enabling robust predictions through real-world experimentation. The presentation, titled 'Novel AI Driven Insights to Guide Early Drug Discovery,' is scheduled for June 3rd at 3:45 PM PDT. This event is a significant platform for biopharmaceutical stakeholders globally.
Predictive Oncology (NASDAQ: POAI) has announced positive outcomes from a retrospective study in partnership with UPMC Magee-Womens Hospital.
The study, which will be presented at the 2024 ASCO Annual Meeting, demonstrated AI-driven multi-omic machine learning models that predict survival outcomes in ovarian cancer patients more accurately than clinical data alone.
Key findings include the use of patient data and sequencing to train 160 models, with seven models showing high prediction accuracy at the two-year threshold and 13 at the five-year threshold.
This advancement offers potential improvements in clinical management and personalized treatment plans.
Presentation details: June 3rd, 9:00am-12:00pm CDT, by Dr. Brian Christopher Orr.
Predictive Oncology (Nasdaq: POAI) reported financial results for Q1 2024, revealing a net loss of $4.2 million on revenue of $0.4 million. The company highlighted key advancements, including the acceptance of a study at the ASCO Annual Meeting, a collaboration with Fujifilm, and progress with FluGen's flu vaccine project. Revenue increased from $239,895 in Q1 2023 to $419,646 in Q1 2024. However, expenses also grew, leading to a higher net loss per share of $(1.04) compared to $(0.86) the previous year. Cash reserves decreased to $5.2 million from $8.7 million at the end of 2023. Gross profit margin improved to 55% from 50% year-over-year.
Predictive Oncology Inc. (NASDAQ: POAI) will report its financial results for the first quarter ended March 31, 2024 on Wednesday, May 15, 2024. The company, known for leveraging AI and machine learning in oncology drug discovery, will host a corporate update conference call and webcast at 8:30 a.m. ET.
Predictive Oncology Inc. announces a collaboration with FluGen to develop a first-of-its-kind intranasal flu vaccine, funded by a $6.2 million Phase 2B grant from the DoD. Predictive Oncology's biologics team will work on creating a stable and soluble formulation for the vaccine, addressing the need for longer shelf-life and global distribution. The project aims to enhance the stability of FluGen's M2SR flu vaccine, enabling advanced clinical trials and promising outcomes.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
What does Predictive Oncology Inc. specialize in?
What are the key segments of Predictive Oncology鈥檚 business?
What recent collaborations has Predictive Oncology announced?
How accurate is Predictive Oncology鈥檚 AI platform PEDAL?
What is the significance of Predictive Oncology鈥檚 3D cell culture model?
How does Predictive Oncology鈥檚 STREAMWAY System benefit the healthcare industry?
What are GPCRs and why are they important in cancer treatment?
What is Predictive Oncology鈥檚 biobank?
Where is Predictive Oncology headquartered?
Who can I contact for investor relations at Predictive Oncology?
